Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Epharm Laboratories

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000598 144 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx144product presentations
G67generic molecules
DF12dosage-form groups
TA14therapeutic areas
PKR144current price records
REG126registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage94%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixEpharm LaboratoriesShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/epharm-laboratoriesGenerated 10 Aug 2026Anti-infectives82 · 57%Cardiovascular17 · 12%Gastrointestinal & hepatology13 · 9%Vitamins, minerals & nutrition9 · 6%Hematology & thrombosis4 · 3%Respiratory & allergy4 · 3%CNS & mental health3 · 2%Other therapeutic areas12 · 8%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioEpharm LaboratoriesDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/epharm-laboratoriesGenerated 10 Aug 2026144presentationsTablet59 · 41%Injection29 · 20%Capsule19 · 13%Syrup8 · 6%Drops7 · 5%Suspension7 · 5%Other forms15 · 10%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionEpharm LaboratoriesCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/epharm-laboratoriesGenerated 10 Aug 2026136comparable productsBelow market median67 · 49%Near market median48 · 35%Above market median21 · 15%Company median price position-4.7%Lowest-price equivalents19Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsEpharm LaboratoriesCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/epharm-laboratoriesGenerated 10 Aug 2026Nabiqasim Industries (Pvt) Ltd.,42 shared63% overlapMediate Pharmaceutical Pvt Ltd39 shared58% overlapNeutro Pharma (Pvt.) Ltd.,38 shared57% overlapCCL Pharmaceuticals (Pvt.) Ltd.37 shared55% overlapZafa Pharmaceutical Laboratories (P…37 shared55% overlapPharmasol (Pvt) Ltd.36 shared54% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives82 products · 57%
Cardiovascular17 products · 12%
Gastrointestinal & hepatology13 products · 9%
Vitamins, minerals & nutrition9 products · 6%
Hematology & thrombosis4 products · 3%
Respiratory & allergy4 products · 3%
CNS & mental health3 products · 2%
Dermatology2 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Fluoroquinolone antibacterials15 products · 10%
Third-generation cephalosporins14 products · 10%
Antimalarials11 products · 8%
Antifungals9 products · 6%
Vitamins / minerals / hematinics9 products · 6%
First-generation cephalosporins6 products · 4%
Aminoglycoside antibacterials5 products · 3%
Macrolide antibacterials5 products · 3%
Formulation footprint

Dosage forms

Tablet59 products
Injection29 products
Capsule19 products
Syrup8 products
Drops7 products
Suspension7 products
Cream4 products
Infusion4 products
Gel2 products
Ointment2 products
Solution2 products
Pessary1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 KeleyCephalexin 6presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Capsule #2 TeltanTelmisartan + Hydrochlorothiazide 5presentations 40 mg + 12.5 mg, 80 mg + 12.5 mg · Tablet #3 AstronMoxifloxacin 4presentations 400 mg, 400 mg/250 mL, 5 mg/mL · Tablet, Infusion, Drops #4 EpanCefixime 4presentations 100 mg/5 mL, 200 mg, 400 mg · Suspension, Capsule #5 FlociprinCiprofloxacin 4presentations 200 mg/100 mL, 250 mg, 500 mg, 750 mg · Infusion, Tablet #6 TaripharmOfloxacin 4presentations 0.3 %, 200 mg, 200 mg/100 mL, 400 mg · Drops, Tablet, Infusion
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median6749% of comparable products
Near market median48within ±5% of median
Above market median2115% of comparable products
Lowest-price equivalents19ties included
Company median price position -4.7% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Keley 500 mgCephalexin · Capsule · 16's PKR 14.49/capsule-52.9% vs market median Ephagent 40 mg/mLGentamicin · Injection · 2mlx25's PKR 11.85/mL-49.8% vs market median Ephagent 40 mg/mLGentamicin · Injection · 2mlx5's PKR 12.23/mL-48.2% vs market median Conate 1 %Clotrimazole · Cream · 15gm PKR 3.20/g-47.3% vs market median PC-Trax 250 mgCeftriaxone · Injection · 1 Vial PKR 104.84/vial/unit-45.4% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 42shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 39shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 38shared generics CCL Pharmaceuticals (Pvt.) Ltd.243 products · 90 generics 37shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.239 products · 98 generics 37shared generics Pharmasol (Pvt) Ltd.251 products · 101 generics 36shared generics
Regulatory & price activity

Observed database signals

Registration numbers126
Price-history records161
Products with price history15
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date30 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

6 results
Intelligence filter: Drug classFirst-generation cephalosporins Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Keley Cephalexin 500 mg Capsule 12's 058417 PKR 396.42 PKR 33.04/capsule 7% above median
Keley Cephalexin 250 mg Capsule 16's 058416 PKR 176.68 PKR 11.04/capsule 30% below median
Keley Cephalexin 500 mg Capsule 16's 058417 PKR 231.91 PKR 14.49/capsule 53% below median
Keley Cephalexin 125 mg/5 mL Dry suspension 60ml 058414 PKR 114.55 PKR 1.91/mL Near median
Keley Cephalexin 250 mg/5 mL Dry suspension 60ml 058415 PKR 198.03 PKR 3.30/mL 10% above median
Keley Cephalexin 250 mg Capsule 12's 058416 PKR 198.03 PKR 16.50/capsule 5% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.